Ph.D., Senior Scientist, Dharmacon, a Horizon Discovery Group Company
Emily has managed projects involving the development and application of gene engineering and gene modulation technologies, including Dharmacon™ ON-TARGETplus™ siRNA and Accell™ siRNA, as well as the introduction of Dharmacon™ Edit-R™, the first rationally-designed, genomewide library of synthetic CRISPRs for gene disruption. She received a Ph.D. in Biochemistry from the University of Colorado at Boulder on the structure and function of protein:single-stranded DNA interactions at telomeres. At Dharmacon she has worked extensively on the mechanism, function, specificity, and delivery of RNA interference (RNAi) and its applications. She is an inventor on several issued patents and has authored peer-reviewed publications related to both RNAi and CRISPR-Cas9.
Presentation Title and Company Description
Emerging Therapeutics Showcase: CRISPR-mediated Transcriptional Activation with Synthetic Guide RNAs
Dharmacon revolutionized RNA synthesis and made key contributions to the RNA interference field while establishing siRNA market leadership. Our CRISPR-Cas9 platform includes predesigned, genomewide, synthetic and lentiviral guide RNAs for knockout or activation, Cas9 nucleases, and knock-in design tools and reagents.